Clinical efficacy of shakubatravalsartan in the treatment of chronic heart failure
Objective To explore the clinical efficacy of shakubatravalsartan in the treatment of chronic heart failure(CHF)caused by dilated cardiomyopathy(DCM)in elderly patients.Methods Ninety elderly patients with CHF caused by DCM were randomly divided into observation and control group,with 45 ones in each.Controls received routine treatment and observation group did shakubatravalsartan on the basis of controls,such indexes were compared between two groups as clinical efficacy,cardiac functions(Left Ventricular End Diastolic Diameter[LVEDD],Left Ventricular Ejection Fraction[LVEF],and Left Ventricular End Systolic Diameter[LVESD]),markers of myocardial injury(high sensitivity cardiac Troponin T[hs-cTnT]and N-Terminal pro-Brain Natriuretic Peptides[NT-proBNP]),inflammatory factors(high-sensitivity C-Reactive Protein[hs-CRP],Interleukin-6[IL-6],and Tumor Necrosis Factor-α[TNF-α]),exercise tolerance(6 Minute Walking Test[6MWT]distance),readmission rates of heart failure,and adverse reactions.Results After treatment,LVESD and LVEDD as well as NT-proBNP,hs-cTnT,IL-6,TNF-α,and hs-CRP lowered,LVEF elevated,6MWT distance increased in both groups compared with pre-treatment,and observation group was better than controls(P＜0.01).The clinical total effective rate was higher in observation than control group(P＜0.05).Intergroup difference in the total incidence of adverse reactions wasn't statistically significant(P＞0.05).The readmission rate of heart failure was lower in observation than control group during 6 month follow-up(P＜0.05).Conclusion Shakubatravalsartan is safe and effective in the treatment of CHF caused by DCM in elderly patients,deserves clinical promotion.
万方数据
维普
